WO2008129874A1 - 腫瘍細胞の標的化方法、及びその用途 - Google Patents

腫瘍細胞の標的化方法、及びその用途 Download PDF

Info

Publication number
WO2008129874A1
WO2008129874A1 PCT/JP2008/000958 JP2008000958W WO2008129874A1 WO 2008129874 A1 WO2008129874 A1 WO 2008129874A1 JP 2008000958 W JP2008000958 W JP 2008000958W WO 2008129874 A1 WO2008129874 A1 WO 2008129874A1
Authority
WO
WIPO (PCT)
Prior art keywords
tumor cell
cell
same
targeting tumor
γδt
Prior art date
Application number
PCT/JP2008/000958
Other languages
English (en)
French (fr)
Inventor
Masato Muto
Mie Nieda
Original Assignee
Medinet Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medinet Co., Ltd. filed Critical Medinet Co., Ltd.
Priority to JP2009510791A priority Critical patent/JPWO2008129874A1/ja
Publication of WO2008129874A1 publication Critical patent/WO2008129874A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

【課題】　腫瘍細胞にγδＴ細胞の標的分子を発現させ、γδＴ細胞が腫瘍細胞を効率よく傷害するための腫瘍細胞の標的化方法を提供するものである。また腫瘍細胞の標的化方法を利用したがん治療・予防薬を提供するものである。さらにがん治療・予防方法を提供するものである。 【解決手段】　腫瘍細胞を代謝拮抗剤に曝露することにより、γδＴ細胞が腫瘍細胞を認識して攻撃するために必要な標的分子を腫瘍細胞表面に発現させることができる。
PCT/JP2008/000958 2007-04-13 2008-04-11 腫瘍細胞の標的化方法、及びその用途 WO2008129874A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009510791A JPWO2008129874A1 (ja) 2007-04-13 2008-04-11 腫瘍細胞の標的化方法、及びその用途

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-106557 2007-04-13
JP2007106557 2007-04-13

Publications (1)

Publication Number Publication Date
WO2008129874A1 true WO2008129874A1 (ja) 2008-10-30

Family

ID=39875404

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/000958 WO2008129874A1 (ja) 2007-04-13 2008-04-11 腫瘍細胞の標的化方法、及びその用途

Country Status (2)

Country Link
JP (1) JPWO2008129874A1 (ja)
WO (1) WO2008129874A1 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201421716D0 (en) * 2014-12-05 2015-01-21 King S College London Cell expansion procedure

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DAUER M. ET AL.: "Evaluation of dendritic cells-based vaccination used in combination with gemcitabine in a murine model of pancreatic carcinoma", GASTROENTEROLOGY, vol. 130, no. 4, SUPPL. 2, 2006, pages A132 *
GROH V. ET AL.: "Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB", PROC. NATL. ACAD. SCI. USA, vol. 96, no. 12, 1999, pages 6879 - 6884, XP002240479 *
KABELITZ D. ET AL.: "Perspectives of gammadelta T Cells in Tumor Immunology", CANCER RESEARCH, vol. 67, no. 1, 2006, pages 5 - 8, XP055069391, DOI: doi:10.1158/0008-5472.CAN-06-3069 *
RAO G. ET AL.: "Up-regulation of MICA/B expression in Panc-1 pancreatic cancer cells by radiation, gemcitabine, and 5-fluorouracil (5-FU)", GASTROENTEROLOGY, vol. 130, no. 4, SUPPL. 2, 2006, pages A907 *
ZHANG B. ET AL.: "Induced sensitization of tumor stroma leads to eradication of established cancer by T cells", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 204, no. 1, 22 January 2007 (2007-01-22), pages 49 - 55 *

Also Published As

Publication number Publication date
JPWO2008129874A1 (ja) 2010-07-22

Similar Documents

Publication Publication Date Title
WO2009006577A3 (en) Compositions and methods for inhibiting ezh2
WO2007081879A3 (en) Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
WO2010056737A3 (en) Methods and compositions involving mirnas in cancer stem cells
WO2009154835A3 (en) Compositions and methods related to mir-16 and therapy of prostate cancer
WO2008021389A3 (en) Using pi3k and mek modulators in treatments of cancer
WO2008103470A3 (en) Oncogenic-ras-signal dependent lethal compounds
WO2006124892A3 (en) Modulators of alpha-synuclein toxicity
WO2012012467A3 (en) Modulation of nuclear-retained rna
WO2008089397A3 (en) Adrb2 cancer markers
WO2010141417A3 (en) Systems and methods for impairing smooth muscle tissue function
IN2012DN02046A (ja)
WO2012145183A3 (en) Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
WO2008058239A9 (en) Spink1 as a prostate cancer marker and uses thereof
WO2011020056A3 (en) Methods of treating cancer using galanin retargeted endpeptidases
IL197633A0 (en) Methods for treating cancer with mva
WO2012006181A3 (en) Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer
WO2010132622A3 (en) Anticd20-cpg conjugates and methods of treating b cell malignancies
WO2010025340A3 (en) Markers and methods for assessing and treating ulcerative colitis and related disorders using a 20 gene panel
WO2010077589A3 (en) Stat3 inhibitors and therapeutic methods using the same
WO2009048980A3 (en) Emp2 antibodies and their therapeutic uses
WO2013036850A3 (en) Modulation of midbody derivatives
WO2010088450A3 (en) Arylamide derivatives useful in the treatment of diseases associated with serca activity
HUE046349T2 (hu) Kompozíciók rákos sejtek kezelésére, és ezek szintézise
EP2144887A4 (en) PHARMACEUTICAL FORMS AND METHOD FOR THE TREATMENT OF CANCER
WO2010054328A3 (en) Compositions and methods for the inhibition of cripto/grp78 complex formation and signaling

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08738564

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009510791

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08738564

Country of ref document: EP

Kind code of ref document: A1